ADIAL PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ADIAL PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.79M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($1.96M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.96M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.23M) | Nov 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.23M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.23M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.19M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.46M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($2.46M) | Nov 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($6.48M) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($6.48M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($6.48M) | Aug 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($1.38M) | Nov 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | $1.09M | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | $1.09M | Aug 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($2.91M) | Aug 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($2.91M) | Nov 13, 2024 |
| Q1 | 2023 | Mar 31, 2023 | ($2.91M) | May 12, 2023 |
| Q3 | 2023 | Sep 30, 2022 | ($3.11M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($3.85M) | Nov 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.76M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.88M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.27M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.21M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.29M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($1.85M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($1.36M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($1.48M) | Aug 13, 2024 |
| Q1 | 2023 | Mar 31, 2023 | ($2.92M) | May 12, 2023 |
| Q3 | 2023 | Sep 30, 2022 | ($2.55M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.24M) | Oct 30, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($3.06M) | May 12, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($4.06M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($4.40M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($4.84M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.34M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($1.82M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($2.30M) | May 17, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($1.75M) | Nov 13, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($2.16M) | Aug 13, 2020 |